ASP-1012 is under clinical development by KaliVir Immunotherapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASP-1012’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KaliVir Immunotherapeutics overview
Kalivir Immunotherapeutics (Kalivir) is a biotechnology company that develops oncolytic viral immunotherapies for cancer. It is investigating VET2-L2, a leptin based drug and VET-S3, a STAT3 (signal transducer and activator of transcription 3) inhibitor to treat metastatic solid tumors resistant to PD1/L1 antibody by destroying cancer cells and activating anti-cancer immunity. The company is also evaluating VET-X1 and VET-X drugs against solid tumors. Kalivir utilizes its proprietary vaccinia enhanced template (VET) platform technology to generate potent novel oncolytic vaccinia viruses with modifications, maximize viral replication and improve intravenous delivery and spread. Kalivir is headquartered in Pittsburgh, Pennsylvania, the US.
For a complete picture of ASP-1012’s drug-specific PTSR and LoA scores, buy the report here.